Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
25.46
-0.04 (-0.16%)
At close: Mar 28, 2025, 4:00 PM
24.79
-0.68 (-2.65%)
Pre-market: Mar 31, 2025, 8:27 AM EDT

Company Description

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Galapagos NV
Galapagos NV logo
Country Belgium
Founded 1999
IPO Date May 6, 2005
Industry Biotechnology
Sector Healthcare
Employees 1,123
CEO Paulus Stoffels

Contact Details

Address:
Generaal De Wittelaan L11 A3
Mechelen, 2800
Belgium
Phone 32 1 534 29 00
Website glpg.com

Stock Details

Ticker Symbol GLPG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
CIK Code 0001421876
CUSIP Number 36315X101
ISIN Number US36315X1019
SIC Code 2834

Key Executives

Name Position
Dr. Paulus A. Stoffels M.D., Ph.D. Chief Executive Officer, Chairman, Interim Head of Research & Development
Valeria Cnossen Executive Vice President and General Counsel
Marieke Vermeersch Head of Corporate Communication
Annelies Missotten Executive Vice President and Chief Human Resources Officer
Ellen Van Der Aar Head of Development
Philippe Alen M.B.A., Ph.D., Pharm.D. Senior Vice President and Head of Business Development
Alice Dietrich Head of Medical Affairs
Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D. Head of Small Molecules Discovery and Senior Vice President
Patrik Ringblom Head of Strategy and US Lead
Dr. Jeevan Shetty Head of Clinical Development Oncology

Latest SEC Filings

Date Type Title
Mar 28, 2025 6-K Report of foreign issuer
Mar 27, 2025 20-F Annual and transition report of foreign private issuers
Feb 24, 2025 6-K Report of foreign issuer
Feb 18, 2025 6-K Report of foreign issuer
Feb 14, 2025 SCHEDULE 13D Filing
Feb 12, 2025 6-K Report of foreign issuer
Jan 10, 2025 SCHEDULE 13D/A Filing
Jan 8, 2025 6-K Report of foreign issuer
Jan 8, 2025 6-K Report of foreign issuer
Dec 9, 2024 6-K Report of foreign issuer